Leveraging strong R&D platforms, Innovent has built a robust pipeline of 25 clinical-stage assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 5 products, including Tyvyt (sintilimab injection, PD-1 antibody), Byvasda (bevacizumab injection), Sulinno (adalimumab injection) and Halpryza (rituximab injection) approved by the National Medicine Products Administration (NMPA) for marketing in Mainland China and IBI375 (Pemigatinib, FGFR1/2/3 inhibitor) approved by Taiwan Food and Drug Administration (TFDA), 6 assets in pivotal clinical trials, and additional 14 molecules in early clinical stage.

Investment Thesis 

A biopharmaceutical pioneer in China 

Tyvyt (sintilimab): first-mover in commercial and clincial 

Three commercial-stage biosimilars to provide strong cashflows 

Blockbuster oncology candidates entering into commercial stage 

Lead positioning in next-generation I/O targets 

Early mover in CAR-T technologies

Targeting broad chronic disease market 

Innovative therapies playing more important role in China 

Financial analysis 

Financial Statements 

Valuation 

Investment risks 

Appendix